The pharmacological effect of BGC20-1531, a novel prostanoid EP receptor antagonist, in the Prostaglandin E human model of headache.
| Autor: | Antonova, Maria, Wienecke, Troels, Maubach, Karen, Thomas, Emma, Olesen, Jes, Ashina, Messoud |
|---|---|
| Předmět: |
ANALYSIS of variance
BLOOD flow measurement VASODILATION CEREBRAL arteries CLINICAL trials CROSSOVER trials HEADACHE HEMODYNAMICS LIQUID chromatography MASS spectrometry HEALTH outcome assessment PROSTAGLANDINS PYRIDINE RESEARCH funding STATISTICAL sampling SELF-evaluation STATISTICS SULFONAMIDES T-test (Statistics) TRANSCRANIAL Doppler ultrasonography DATA analysis TREATMENT effectiveness REPEATED measures design BLIND experiment SEVERITY of illness index DATA analysis software PHARMACODYNAMICS EVALUATION PREVENTION |
| Zdroj: | Journal of Headache & Pain; Oct2011, Vol. 12 Issue 5, p551-559, 9p |
| Abstrakt: | Using a human Prostaglandin E (PGE) model of headache, we examined whether a novel potent and selective EP receptor antagonist, BGC20-1531, may prevent headache and dilatation of the middle cerebral (MCA) and superficial temporal artery (STA). In a three-way cross-over trial, eight healthy volunteers were randomly allocated to receive 200 and 400 mg BGC20-1531 and placebo, followed by a 25-min infusion of PGE. We recorded headache intensity on a verbal rating scale, MCA blood flow velocity and STA diameter. There was no difference in headache response or prevention of the dilation of the MCA or the STA ( P > 0.05) with either dose of BGC20-1531 relative to placebo, although putative therapeutic exposures were not reached in all volunteers. In conclusion, these data suggest that the other EP receptors may be involved in PGE induced headache and dilatation in normal subjects. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink